Belite Bio, a clinical-stage drug development company, announced it will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company is advancing tinlarebant, an oral therapy for degenerative retinal diseases including Stargardt disease type 1 and geographic atrophy, with completed Phase 3 trials and ongoing Phase 2/3 and Phase 3 trials.

Belite Bio announced the completion of its rolling NDA submission to the FDA for tinlarebant, an oral therapy for Stargardt disease type 1 (STGD1), a rare inherited retinal disease affecting approximately 53,000 people in the U.S. with no current approved treatments. The submission was made under Breakthrough Therapy Designation and will undergo a 60-day FDA review period. The Phase 3 DRAGON trial demonstrated tinlarebant's ability to significantly reduce the growth rate of retinal lesions compared to placebo.

Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant to treat Stargardt disease type 1 (STGD1), with completion expected in Q2 2026. The company reported Q1 2026 results showing $798.6 million in cash and investments, increased R&D and SG&A expenses due to commercialization preparation and team expansion, and a net loss of $26.9 million (GAAP). Key commercial leadership positions have been hired as the company prepares for potential market launch.

Belite Bio announced that tinlarebant, its lead product candidate for Stargardt disease, has received orphan drug status from Switzerland's Swissmedic. The drug previously demonstrated a 35.7% reduction in retinal lesion growth rate in the Phase 3 DRAGON trial and has received multiple regulatory designations including Breakthrough Therapy and Fast Track designations in the U.S. The company is rolling out an NDA submission with the FDA expected to complete in Q2 2026.

Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company developing therapeutics for degenerative retinal diseases, announced a webcast scheduled for May 20, 2026, at 4:30 p.m. ET to discuss Q1 2026 financial results and provide a business update. The company's lead candidate, tinlarebant, is being evaluated in Phase 2/3 and Phase 3 trials for Stargardt disease type 1 and geographic atrophy.

Belite Bio has initiated a rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, an oral therapy for treating Stargardt disease type 1 (STGD1). The drug has received Breakthrough Therapy Designation and could become the first approved treatment for this rare inherited retinal disorder. The company expects to complete the NDA submission in Q2 2026 and is preparing for potential commercialization in 2027.

Belite Bio has priced a public offering of 2,272,727 American Depositary Shares at $154.00 per share, expecting to raise approximately $350 million to fund commercialization preparation, pipeline development, and general corporate purposes.

The geographic atrophy market is expected to grow significantly due to rising global prevalence, aging populations, and emerging therapies targeting this advanced form of age-related macular degeneration.

The dry AMD market is expected to grow significantly by 2034, driven by emerging therapies, increasing diagnosis rates, and novel treatment approaches targeting geographic atrophy.

Belite Bio received conditional marketing authorization from the UK's MHRA for Tinlarebant, a potential treatment for Stargardt disease, based on interim Phase 3 DRAGON trial results. The company expects final topline data in Q4 2025.

Belite Bio received priority review from China's NMPA for Tinlarebant, a novel oral therapy for treating Stargardt disease, based on positive interim Phase 3 trial results. The company expects final topline data in Q4 2025.

The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.